No Data
No Data
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
Design Therapeutics Reports Q3 EPS (23c), Consensus (24c)
Design Therapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (DSGN) DESIGN THERAPEUTICS Posts Q3 Loss $-0.23